Replies to post #92287 on Avid Bioservices Inc (CDMO)

[jakedogman1]

but by combining don't you increase the "N" which makes the results more significant?

[geocappy1]

IMO we are looking better every day. If we make it to the ESMO w/o triggering the 2nd line MOS or the 1st line lung cancer trial MOS, the proof of concept continues to build as data results back up the MOA of Bavi.

At that point it is hard to deny that bavi has efficacy. We would be at 14-15.5 months for 2nd line MOS, 15-16.5months for 1st line (if math correct) and IMO we probably show efficacy in the HepC trial (slower working).

Seems to me it won't be if a partner wants to partner but how to structure an agreement on the value that is fair to both parties.

[entdoc]

rrdog, may be a small difference in side-effect profile in the two dosage levels.p we'll have to see how that plays out

[freethemice]

Using radiation does increase the amount of PS exposed. However, in the second-line NSCLC trial about 91%
of the patients had metastatic disease. Usually radiation is not used in these cases, but in earlier stages of the
disease. So future trials using radiation will most likely be in patients with stages 1-3, and then using bavi might
have the real potential of stopping transition to stage 4. There will still be a need for bavi plus chemo in the
stage 4 population. My guess is that they will use the 3 mg/kg dose in the phase 3 trial. A lower dose might work
very well with radiation in the future.